NCT07229534Not yet recruitingPhase 4
Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes
A Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 238 (estimated)
- First submitted
- 13 Nov 2025
- Start date
- Nov 2025
- Primary completion date
- Nov 2027
- Lead sponsor
- Dong-A ST Co., Ltd.
- Diseases
- Type 2 diabetes
- NCT number
- NCT07229534
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 238
- From Nov 2025 to the primary completion date, Nov 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
Lab values
- eGFR\<45mL/min/1.73m2
- ALT and AST 3 times or higher than upper normal range
Other
- Determined by investigator as unfit to participate in a clinical trial due to other reasons
Who the study is looking for
- 7.0%≤HbA1c≤10.5% and fasting glucose≤270mg/dL
- Treated with 1,000mg/day dose of metformin for at least 8 weeks
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.